Boehringer Ingelheim swapped its consumer healthcare products for animal health products from Sanofi Aventis. This means, Boehringer Ingelheim sold its consumer healthcare products range to Sanofi while Sanofi on the other hand sold its animal health part to Boehringer.
Sanofi and Boehringer Ingelheim confirm Closing of the deal on January 1st 2017.
Sanofi Aventis is known for offering the most advanced, exceptionally versatile and superior pharmaceutical products. This is a great opportunity for Sanofi since it’s dominating the African market as leading supplier of human health products. Sanofi’s excellent strategy in marketing has achieved this position in the market and won the respect of its partners through its varied range of products, setting itself quality standards and constantly translating new knowledge into products and services.
Sanofi has been doing well with it’s Rhinathiol range of products therefore with new products on board we expect a good business venture for them. Fast moving Boehringer’s products like buscopan, mucosolvan e.t.c will be under Sanofi. Sanofi has recently lanched a new product “Maalox stick” to the Kenyan market which is already doing well.
It’s exciting that Sanofi will continue to provide high-quality and cost effective products for treatment and management of diseases hence promoting fast and early prevention of these diseases. This will ensure the best possible outcomes and comfort to the patient.